Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.
Shi ZY, Fang Y, Xu PP, Yi HM, Li JF, Dong Y, Zhu Y, Liu MK, Fu D, Wang S, Shi Q, Shen R, Zhong HJ, Wang CF, Cheng S, Wang L, Liu F, Zhao WL.
Shi ZY, et al. Among authors: liu mk.
Clin Transl Med. 2024 Jun;14(6):e1691. doi: 10.1002/ctm2.1691.
Clin Transl Med. 2024.
PMID: 38812093
Free PMC article.
No abstract available.